0000950170-24-003466.txt : 20240109
0000950170-24-003466.hdr.sgml : 20240109
20240109185231
ACCESSION NUMBER: 0000950170-24-003466
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240105
FILED AS OF DATE: 20240109
DATE AS OF CHANGE: 20240109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Townsend Richard Nolan
CENTRAL INDEX KEY: 0001995218
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41855
FILM NUMBER: 24524480
MAIL ADDRESS:
STREET 1: C/O LEXEO THERAPEUTICS, INC.
STREET 2: 345 PARK AVENUE SOUTH, 6TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lexeo Therapeutics, Inc.
CENTRAL INDEX KEY: 0001907108
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 854012572
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: FLOOR 6
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: (212) 547-9879
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: FLOOR 6
CITY: NEW YORK
STATE: NY
ZIP: 10010
4
1
ownership.xml
4
X0508
4
2024-01-05
0001907108
Lexeo Therapeutics, Inc.
LXEO
0001995218
Townsend Richard Nolan
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6
NEW YORK
NY
10010
true
true
false
false
Chief Executive Officer
true
Common Stock
2024-01-05
4
A
false
43750
0
A
170695
D
Stock Option (Right to Buy)
14.48
2024-01-05
4
A
false
262500
0
A
2034-01-04
Common Stock
262500
262500
D
The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
Total represents 126,945 shares of Common Stock and 43,750 RSUs.
25% of the shares underlying the option shall vest on January 5, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
/s/ Jenny Robertson, Attorney-in-Fact
2024-01-09